# RE-LuPSMA (NCT06288113)

> Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

No report yet. It can be ordered.

- Drugs tested: lutetium lu 177 vipivotide tetraxetan
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06288113
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Jonsson Comprehensive Cancer Center
- Conditions: Castration-Resistant Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8
- Interventions: Biospecimen Collection; Computed Tomography; Gallium Ga 68 Gozetotide; Lutetium Lu 177 Vipivotide Tetraxetan; Positron Emission Tomography; Questionnaire Administration; Single Photon Emission Computed Tomography
- Enrollment: 40
- Primary outcome: 12-month overall survival

## Indexed commentary on RE-LuPSMA so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X
- 2 YouTube videos

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=re-lupsma-nct06288113
